Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine. …read more

Source: EurekAlert

(Visited 1 times, 1 visits today)

Popular Posts